Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-09-26
2006-09-26
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S387300, C530S395000, C424S134100, C424S184100, C424S185100, C424S192100
Reexamination Certificate
active
07112655
ABSTRACT:
A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are a polypeptide of the cell surface molecule; a polypeptide fragment thereof; a fusion polypeptide comprising the fragment; a pharmaceutical composition comprising any one of the above; and methods of using the compositions.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 6075181 (2000-06-01), Kucherlapati
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2002/0177191 (2002-11-01), Kroczek
patent: 2002/0182667 (2002-12-01), Kroczek
patent: 9913320 (1999-04-01), None
patent: 19821060 (1999-04-01), None
patent: 0 984 023 (2000-03-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/11909 (1998-03-01), None
patent: WO 98/19706 (1998-05-01), None
patent: WO 98/37415 (1998-08-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: 1 125 585 (2001-08-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/44364 (2002-06-01), None
patent: WO 02/70010 (2002-09-01), None
patent: WO 02/76504 (2002-10-01), None
Bajorath J. Mol. Modeling 199; 5:169-176.
Hutloff et al. Nature Jan. 1999, 397:263-266
Mages et al. Eur. J. Immunol. Apr. 2000; 30:1040-1047.
Ozkaynak et al. Nat. Immunol. 2001; 2(7):591-596.
J. Robert et al.,Antibody Cross-Linking of the Thymocyte-Specific Cell Surface Molecule CTX Causes Abnormal Mitosis and Multinucleation of Tumor Cells, Experimental Cell Research, vol. 235, pp. 227-237, 1997.
S.D. Heyeck et al.,Developmental regulation of a murine T-cell-specific tyrosine kinase gene, Tsk, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 669-673, 1993.
D. Marguet et al.,cDNA Cloning for Mouse Thymocyte-activating Molecule, The Journal of Biological Chemistry, vol. 267, No. 4, pp. 2200-2208, 1992.
Buonfiglio, D. et al., “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical”, Eur. J. Immunol., 30:3463-3467, 2000.
Redoglia, V. et al., “Characterization of H4: a mouse T lymphocyte . . . ”, Eur. J. Immunol., 26:2781-2789, 1996.
Cocks et al., “A novel receptor involved in T-cell activation,” NATURE, 376:260-263 (Jul. 20, 1995).
Kuchroo et al., “B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy,” CELL, 80:707-718 (Mar. 10, 1995).
Nojima et al., “The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion,” Cellular Immunology, 152:249-260 (1993).
Sharpe, “Analysis of lymphocyte costimulationin vivousing transgenic and ‘knockout’ mice,” Current Opinion in Immunology, 7:389-395 (1995).
Tai et al., “A role for CD9 molecules in T cell activation,” J. Exp. Med., 184:753-758 (Aug. 1996).
Tamatani et al., “AILIM/ICOS: a novel lymphocyte adhesion molecule,” International Immunology, 12(1):51-55 (2000).
Tezuka et al., “Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family,” Biochemical and Biophysical Research Communications, 276:335-345 (2000).
Aicher et al., “Characterization of Human Inducible Costimulator Ligand Expression and Function,” J. Immunol., 164(9):4689-4696 (2000).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol., 30(12):3707-3717 (2000).
Brodie et al., “LICOS, a primordial costimulatory ligand?” Current Biology, 10(6):333-336 (2000).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol., 29(9)2863-2874 (1999).
Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).
Chambers, “The Expanding world of co-stimulation: the two-signal model revisited,” Trends in Immunology, 22(4):217-223 (2001).
Coyle et al., “The CD28-Related Molecule ICOS Is Required for Effective T Cell-Dependent Immune Responses,” IMMUNITY, 13:95-105, (2000).
Dong et al., “Cutting Edge: Critical Role of Inducible Costimulator in Germinal Center Reactions,” J. Immunol., 166(6):3659-3662 (2001).
Dong, “ICOS co-stimulatory receptor is essential for T-cell activation and function,” NATURE 409(6816):97-101 (2001).
Gonzalo et al., “The Related Molecules CD28 and Inducible Costimulator Deliver Both Unique and Complementary Signals Required for Optimal T Cell Activation,” J. Immunol., 166(1):1-5 (2001).
Guo et al., “Stimulatory Effects of B7-Related Protein-1 on Cellular and Humoral Immune Responses in Mice,” J. Immunol., 166(9):5578-5584 (2001).
Hanzawa et al., “Characteristics of a TTH1 antibody which blocks an unknown adhesion phenomenon,” Proceedings of the Japanese Society for Immunology, vol. 24, Abstract No. W17-13 (1994) [Original Japanese and English Language Translation].
Houdebine “Production of pharmaceutical proteins from transgenic animals” J. Biotechnol. 34:269-87 (1994).
Ishikawa et al., “Prediction of the Coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteinsin vitro,” DNA Research, 5:169-176 (1998).
Kappel et al. “Regulating gene expression in transgenic animals” Current Opinion in Biotechnology 3:548-53 (1992).
Kopf et al., “Inducible Costimulator Protein (ICOS) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection,” J. Exp. Med., 192(1):53-61 (2000).
Ling et al., “Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor,” J. Immunol., 164(4):1653-1657 (2000).
McAdam, “ICOS is critical for CD40-mediated antibody class switching,” NATURE 409(6816):102-105 (2001).
McAdam, “Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+T Cells,” J. Immunol., 165(9):5035-5040 (2000).
McAdam et al., “Mouse inducible costimulatory (ICOS) molecule expression is increassed by CD28 costimulation and regulates development of the Th2 cells,” FASEB Journal, 14(6):A1169 (2000).
Mueller, “T cells: A proliferation of costimulatory molecules,” Curr. Biol. 10(6):R227-R230 (2000).
Mullins et al. “Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice” EMBO J., 8:4065-72 (1989).
Mullins et al. “Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene” NATURE, 344:541-44 (1990).
Mullins et al. “Transgenesis in nonmurine species” Hypertension 22:630-33 (1993).
Niemann “Transgenic farm animals get off the ground” Transgenic Research, 7:73-75 (1998).
Overbeek “Factors affecting transgenic animal p
Tamatani Takuya
Tezuka Katsunari
Gambel Phillip
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
JTT-1 protein and methods of inhibiting lymphocyte activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with JTT-1 protein and methods of inhibiting lymphocyte activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and JTT-1 protein and methods of inhibiting lymphocyte activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3535289